Regulatory Story

RNS Number : 2885Y
Shield Therapeutics PLC
08 May 2019

Shield Therapeutics plc

("Shield" or the "Group")


Appointment of Joint Broker


London, UK, 8 May 2019:  Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces the appointment of finnCap Ltd as its joint broker with immediate effect.


- Ends -


For further information please contact:


Shield Therapeutics plc

 Carl Sterritt, Chief Executive Officer

+44 (0)20 71868500

Tim Watts, Chief Financial Officer

Nominated Advisor and Joint Broker

Peel Hunt LLP

James Steel/Dr Christopher Golden                                                

+44 (0)20 74188900

Joint Broker

finnCap Ltd

                                                             +44 (0)20 72200500

Geoff Nash /Matt Radley/ Alice Lane                                    

Financial PR & IR Advisor

Walbrook PR

+44 (0)20 79338780 or

Paul McManus / Helen Cresswell

+44 (0)7980 541893 / +44 (0)7841 917679


About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.  For more information please visit 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit